Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CYTK
CYTOKINETICS, INCORPORATED
NASDAQ
$72.09
▼ DOWN 7.46% (-5.81)

KEY STATISTICS

Market Cap$8.97 B
52w High$88.31
52w Low$44.91
Dividend Yield—
Frequency—
P/E-9.98
Volume4.36M
Shares Out.124.43M

COMPANY

LEADERSHIP

Robert I. Blum
CHIEF EXECUTIVE
Robert I. Blum

COMPENSATION 2026

Salary$591,667
Stock Awards$0
Incentive Plan Pay$0
All Other Comp.$0
Total$2,177,957

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 26, 2004
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
673

PRICE TARGET

Target High$140.00
Target Low$84.00
Target Median$112.00
Target Consensus$109.91

UPCOMING EARNINGS

DateNov 4, 2026
DayWednesday
Rev. Est.$39.77M
NOV
4
WED

SPLIT RECORD

DATETYPERATIO
2013-06-25Reverse1:6

PRICE

$72.09 ▼ DOWN 7.46% (−$5.81)
OVERLAYS
$72.00$72.75$73.50$74.259:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM72.09

About Cytokinetics, Incorporated

https://www.cytokinetics.com ↗

Cytokinetics, a late-stage biopharmaceutical firm, develops muscle-targeting small molecules like omecamtiv mecarbil and reldesemtiv for diseases such as heart failure and ALS, with several candidates in Phase III trials.

INDUSTRY

Biotechnology

A PRODUCT CYTOKINETICS, INCORPORATED IS KNOWN FOR

MYQORZO® (aficamten)
MYQORZO® (aficamten)

Aficamten, developed by Cytokinetics, is a Chinese-approved cardiac myosin inhibitor for symptomatic obstructive hypertrophic cardiomyopathy, improving symptoms and functional capacity, and serving as a key late-stage asset for the company.

COMPETITORS

COMPETITOR
BMY COMPARE
EWTX COMPARE
NVS COMPARE
RVMD COMPARE
TNYA COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Net Product Revenue— — $4.79M $25.33M ▲
Collaboration Revenues$1.94M $4.33M ▲$2.64M ▼$3.29M ▲

Revenue by Geography

MapREGIONQ3-2025Q4-2025Q1-2026Q2-2026
CHINA$400K $200K ▼$500K ▲$800K ▲

ETFS HOLDING THIS STOCK

ETFS HOLDING
232
LISTED HERE
26
RANKED BY POSITION SIZE
IJH.AX
0.29% · 4.7M
VTS.AX
0.01% · 4.3M
XBI
1.03% · 1.6M
TCAF
1.13% · 1.2M
SCHA
0.22% · 645.1K
FESM
0.37% · 311.6K
XRSU.L
0.32% · 129.9K
NUSC
0.60% · 117.7K
QMOM
1.79% · 105.3K
RSSL
0.30% · 63.1K
PTH
1.68% · 63.0K
LFSC
3.54% · 62.2K
JHMM
0.08% · 61.0K
LABU
0.70% · 57.4K
BBMC
0.19% · 55.9K
FNY
0.67% · 53.9K
GSC
1.05% · 38.2K
WSCSRI.SW
0.33% · 34.5K
VALT
0.94% · 28.8K
HRTS
3.56% · 27.6K
BBP
1.36% · 20.9K
BKMC
0.22% · 20.4K
AFTY
0.22% · 17.3K
IQSM
0.31% · 15.1K
NBCR
0.13% · 14.6K
ZMID.TO
0.27% · 9.5K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
94.14%
HOLDERS
664
TOP 12 OF 664 · RANKED BY POSITION SIZE
Blackrock, Inc.
20.1M sh · $1.71B
T. Rowe Price Investment Management, Inc.
19.1M sh · $1.05B
Blackrock Inc.
14.7M sh · $794.97M
Fmr LLC
13.1M sh · $719.52M
Vanguard Group Inc
12.0M sh · $765.54M
Wellington Management Group Llp
8.0M sh · $527.91M
State Street Corp
6.5M sh · $553.24M
Tudor Investment Corp Et Al
6.0M sh · $6.86M
Avoro Capital Advisors LLC
5.0M sh · $425.95M
Bank Of America Corp /De/
4.6M sh · $394.92M
Deep Track Capital, LP
4.3M sh · $236.33M
Geode Capital Management, LLC
3.7M sh · $316.33M

RATINGS SNAPSHOT

Overall rating: C

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity5
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score2

TRADES BY CONGRESS

HOUSE TRADES
Gilbert Cisneros
Gilbert Cisneros
Purchase
2026-06-30
 Lisa McClain
Lisa McClain
Sale (Full)
2025-06-17

INSIDER TRADES

★
OFFICER: EVP RESEARCH & DEVELOPMENT
Malik Fady Ibraham
Purchase · 3.5K shares
2026-08-18
★
OFFICER: EVP RESEARCH & DEVELOPMENT
Malik Fady Ibraham
Sale · 3.5K shares
2026-08-18
★
DIRECTOR, OFFICER: PRESIDENT & CEO
Blum Robert I
Purchase · 7.5K shares
2026-08-10
★
DIRECTOR, OFFICER: PRESIDENT & CEO
Blum Robert I
Sale · 7.5K shares
2026-08-10

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 8
OVERWEIGHT 4
OUTPERFORM 4
MARKET OUTPERFORM 2
NEUTRAL 1
19 GRADES IN THE LAST 12 MONTHS
Barclays OVERWEIGHT JP Morgan OVERWEIGHT Truist Securities BUY RBC Capital OUTPERFORM Citizens MARKET OUTPERFORM Needham BUY UBS BUY Mizuho OUTPERFORM

SECTORS PEERS

PEERPRICE
JAZZ$244.54COMPARE
HALO$105.35COMPARE
CORT$113.88COMPARE
AXSM$199.02COMPARE
ABVX$113.35COMPARE
RYTM$107.17COMPARE
CRSP$57.72COMPARE